NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2021 and 2020
(Amounts
and shares in thousands, except per share amounts)
(UNAUDITED)
NOTE 1 –
DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION
Description of
Business
Effective
July 1, 2015, the Company restructured the corporate organization of the management of diagnostic imaging centers segment of our business.
The reorganization was structured to more completely integrate the operations of Health Management Corporation of America and HDM. Imperial
contributed all of its assets (which were utilized in the business of Health Management Corporation of America) to HDM and received a
24.2% interest in HDM. Health Management Corporation of America retained a direct ownership interest of 45.8% in HDM, and the original
investors in HDM retained a 30.0% ownership interest in the newly expanded HDM. During the six months ended December 31, 2021, the Company
purchased non-controlling interests from the minority shareholders for $546,000. Currently the Company has a direct ownership interest
of 70.8% and the investors’ have a 29.2% ownership interest. The entire management of diagnostic imaging centers business segment
is now being conducted by HDM, operating under the name “Health Management Company of America”.
Basis of Presentation
The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting
principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they
do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America
for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered
necessary for a fair presentation have been included. Operating results for the three and six months ended December 31, 2021, are not
necessarily indicative of the results that may be expected for the fiscal year ending June 30, 2022. For further information, refer to
the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K filed on October
13, 2021 for the fiscal year ended June 30, 2021.
During
March 2020, the global pandemic of COVID-19 has caused turbulence and uncertainty in the United States and international markets and
economies which has adversely effected our workforce, liquidity, financial conditions, revenues, profitability and business operations.
Generally COVID-19 had caused us to require that much of our workforce work from home and has restricted the ability of our personnel
to travel for marketing purposes or to service our customers. At the end of fiscal year ending June 30, 2020, the Company was able to
enact certain decisions to allow the Company to survive during the global pandemic and from further losses or additional decreases in
scan volume. The Company also received some government stimulus funds from the Paycheck Protection Program (“PPP”) and Medicare
advances/stimulus payments. During the six months ended December 31, 2021 the PPP loan was forgiven in its entirety. During fiscal 2022,
the Company had to deal with the increased strictness in the enforcement of COVID-19 mandates, such as the requirement that employees
in healthcare facilities be vaccinated, along with the newer omicrom variant that is more transmissible. As a result, the Company experienced
absences due to illness and the loss of unvaccinated employees whose duties required them to be in contact with patients. Due to these
conditions, the Company was sometimes unable to keep scanning facilities open for all shifts and as a result there was a slight decrease
in scans during the second quarter of fiscal 2022. The Company has been able to navigate through these challenges and avoid any significant
disruption of the business and the volume has recently risen back almost to pre- COVID-19 levels. Although we are unable to predict if
there will be additional consequences on our operations from the continuing global pandemic of COVID-19, the Company believes with positive
cash flows, low debt and cash on hand, it will be able to continue operations going forward.
FONAR
CORPORATION AND SUBSIDIARIES
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2021 and 2020
(Amounts
and shares in thousands, except per share amounts)
(UNAUDITED)
NOTE
2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Principles of
Consolidation
The
unaudited condensed consolidated financial statements include the accounts of FONAR Corporation, its majority and wholly-owned subsidiaries
and partnerships (collectively the “Company”). All significant intercompany accounts and transactions have been eliminated
in consolidation.
Revenues
The
revenue recognition standard in ASC 606 outlines a single comprehensive model for recognizing revenue as performance obligations, defined
in a contract with a customer as goods or services transferred to the customer in exchange for consideration, are satisfied. The standard
also requires expanded disclosures regarding the Company’s revenue recognition policies and significant judgements employed in
the determination of revenue.
Our
revenues generally relate to net patient fees received from various payers and patients themselves under contracts in which our
performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to
provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period
of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid,
managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the
transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed
care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the
services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide
for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews
the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care
contractual terms resulting from contract renegotiations and renewals.
BUSINESS
COMBINATION
When
the qualifications for business combination accounting treatment are met, it requires us to recognize separately from goodwill the assets
acquired and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess
of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While
we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates
are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the
acquisition date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon
the conclusion of the measurement period of final determination of the values of assets acquired or liabilities assumed, whichever comes
first, any subsequent adjustments are recorded to our consolidated statements of operations.
FONAR
CORPORATION AND SUBSIDIARIES
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2021 and 2020
(Amounts
and shares in thousands, except per share amounts)
(UNAUDITED)
NOTE 2 - SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Earnings
Per Share
Basic
earnings per share (“EPS”) is computed based upon the weighted average number of shares of common stock and stock equivalents
outstanding, net of common stock. In accordance with ASC topic 260-10, “Participating Securities and the Two-Class method”,
the Company used the Two-Class method for calculating basic income per share and applied the if converted method in calculating diluted
income per share for the three and six months ended December 31, 2021 and 2020.
Diluted
EPS reflects the potential dilution from the exercise or conversion of all dilutive securities into common stock based on the average
market price of common shares outstanding during the period. For the three and six months ended December 31, 2021 and 2020, diluted EPS
for common shareholders includes 128 shares upon conversion of Class C Common.
Earnings
Per Share
Earnings Per Share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three
months ended
December 31, 2021
|
|
Three
months ended
December 31, 2020
|
|
|
Total
|
|
Common
Stock
|
|
Class
C Common
Stock
|
|
Total
|
|
Common
Stock
|
|
Class
C Common
Stock
|
Basic
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Numerator:
Net income available to common stockholders
|
|
$
|
4,020
|
|
|
$
|
3,777
|
|
|
$
|
62
|
|
|
$
|
3,111
|
|
|
$
|
2,923
|
|
|
$
|
48
|
|
Denominator:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average
shares outstanding
|
|
|
6,554
|
|
|
|
6,554
|
|
|
|
383
|
|
|
|
6,465
|
|
|
|
6,465
|
|
|
|
383
|
|
Basic income per
common share
|
|
$
|
0.61
|
|
|
$
|
0.58
|
|
|
$
|
0.16
|
|
|
$
|
0.48
|
|
|
$
|
0.45
|
|
|
$
|
0.12
|
|
Diluted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator:
Weighted average shares outstanding
|
|
|
|
|
|
|
6,554
|
|
|
|
383
|
|
|
|
|
|
|
|
6,465
|
|
|
|
383
|
|
Convertible
Class C Stock
|
|
|
|
|
|
|
128
|
|
|
|
—
|
|
|
|
|
|
|
|
128
|
|
|
|
—
|
|
Total
Denominator for diluted earnings per share
|
|
|
|
|
|
|
6,682
|
|
|
|
383
|
|
|
|
|
|
|
|
6,593
|
|
|
|
383
|
|
Diluted income
per common share
|
|
|
|
|
|
$
|
0.57
|
|
|
$
|
0.16
|
|
|
|
|
|
|
$
|
0.44
|
|
|
$
|
0.12
|
|
FONAR
CORPORATION AND SUBSIDIARIES
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2021 and 2020
(Amounts
and shares in thousands, except per share amounts)
(UNAUDITED)
NOTE 2 - SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Earnings
Per Share (Continued)
|
|
Six
months ended
December 31, 2021
|
|
Six
months ended
December 31, 2020
|
|
|
Total
|
|
Common
Stock
|
|
Class
C Common
Stock
|
|
Total
|
|
Common
Stock
|
|
Class
C Common
Stock
|
Basic
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Numerator:
Net income available to common stockholders
|
|
$
|
7,907
|
|
|
$
|
7,430
|
|
|
$
|
122
|
|
|
$
|
5,619
|
|
|
$
|
5,281
|
|
|
$
|
86
|
|
Denominator:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average
shares outstanding
|
|
|
6,554
|
|
|
|
6,554
|
|
|
|
383
|
|
|
|
6,456
|
|
|
|
6,456
|
|
|
|
383
|
|
Basic income per
common share
|
|
$
|
1.21
|
|
|
$
|
1.13
|
|
|
$
|
0.32
|
|
|
$
|
0.87
|
|
|
$
|
0.82
|
|
|
$
|
0.23
|
|
Diluted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator:
Weighted average shares outstanding
|
|
|
|
|
|
|
6,554
|
|
|
|
383
|
|
|
|
|
|
|
|
6,456
|
|
|
|
383
|
|
Convertible
Class C Stock
|
|
|
|
|
|
|
128
|
|
|
|
—
|
|
|
|
|
|
|
|
128
|
|
|
|
—
|
|
Total
Denominator for diluted earnings per share
|
|
|
|
|
|
|
6,682
|
|
|
|
383
|
|
|
|
|
|
|
|
6,584
|
|
|
|
383
|
|
Diluted income
per common share
|
|
|
|
|
|
$
|
1.11
|
|
|
$
|
0.32
|
|
|
|
|
|
|
$
|
0.80
|
|
|
$
|
0.23
|
|
Recent Accounting
Pronouncements
FASB,
the Emerging Issues Task Force and the SEC have issued certain other accounting standards, updates, and regulations as of December 31,
2021 that will become effective in subsequent periods; however, management does not believe that any of those updates would have significantly
affected our financial accounting measures or disclosures had they been in effect during 2021 or 2020, and it does not believe that any
of those pronouncements will have a significant impact on our consolidated condensed financial statements at the time they become effective.
FONAR
CORPORATION AND SUBSIDIARIES
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2021 and 2020
(Amounts
and shares in thousands, except per share amounts)
(UNAUDITED)
NOTE
3 – ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE
Receivables,
net is comprised of the following at December 31, 2021, and June 30, 2021:
Receivables
- Non Current - net
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December
31, 2021
|
|
|
Gross
Receivable
|
|
Allowance
for doubtful accounts
|
|
Net
|
Accounts
receivable
|
|
$
|
4,477
|
|
|
$
|
371
|
|
|
$
|
4,106
|
|
Accounts
receivable - related party
|
|
$
|
60
|
|
|
|
—
|
|
|
$
|
60
|
|
Medical
receivable
|
|
$
|
18,775
|
|
|
$
|
—
|
|
|
$
|
18,775
|
|
Management
and other fees receivable
|
|
$
|
48,943
|
|
|
$
|
16,807
|
|
|
$
|
32,136
|
|
Management
and other fees receivable from related medical practices (“PC’s”)
|
|
$
|
12,280
|
|
|
$
|
3,987
|
|
|
$
|
8,293
|
|
|
|
June
30, 2021
|
|
|
Gross
Receivable
|
|
Allowance
for doubtful accounts
|
|
Net
|
Accounts
receivable
|
|
$
|
4,968
|
|
|
$
|
442
|
|
|
$
|
4,526
|
|
Accounts
receivable - related party
|
|
$
|
12
|
|
|
|
—
|
|
|
$
|
12
|
|
Medical
receivable
|
|
$
|
17,901
|
|
|
$
|
—
|
|
|
$
|
17,901
|
|
Management
and other fees receivable
|
|
$
|
46,735
|
|
|
$
|
15,787
|
|
|
$
|
30,948
|
|
Management
and other fees receivable from related medical practices (“PC’s”)
|
|
$
|
11,998
|
|
|
$
|
4,184
|
|
|
$
|
7,814
|
|
The Company’s
customers are concentrated in the healthcare industry.
Accounts Receivable
Credit
risk with respect to the Company’s accounts receivable related to product sales and service and repair fees is limited due to the
customer advances received prior to the commencement of work performed and the billing of amounts to customers as sub-assemblies are
completed. Service and repair fees are billed on a monthly or quarterly basis and the Company does not continue providing these services
if accounts receivable become past due. The Company controls credit risk with respect to accounts receivable from service and repair
fees through its credit evaluation process, credit limits, monitoring procedures and reasonably short collection terms. The Company performs
ongoing credit authorizations before a product sales contract is entered into or service and repair fees are provided.
FONAR
CORPORATION AND SUBSIDIARIES
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2021 and 2020
(Amounts
and shares in thousands, except per share amounts)
(UNAUDITED)
NOTE 3 –
ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (CONTINUED)
Long
Term Accounts Receivable
The
Company will generate revenue from long-term, non-cancellable contracts to provide service and repair services. Future revenue to be
recognized over the following four years as of December 31, 2021 is as follows:
Total
Facilities
|
|
|
|
|
|
2023
|
|
|
$
|
1,020
|
|
2024
|
|
|
|
944
|
|
2025
|
|
|
|
289
|
|
2026
|
|
|
|
37
|
|
Total
|
|
|
$
|
2,290
|
|
Medical Receivables
Medical
receivables are due under fee-for-service contracts from third party payors, such as hospitals, government sponsored healthcare programs,
patient’s legal counsel and directly from patients. Substantially all the revenue relates to patients residing in Florida. The
carrying amount of the medical receivable is reduced by an allowance that reflects management’s best estimate of the amounts that
will not be collected. The Company determines allowances for contractual adjustments and uncollectible accounts based on specific agings,
specific payor collection issues that have been identified and based on payor classifications and historical experience at each site.
Management and
Other Fees Receivable
The
Company’s receivables from the related and non-related professional corporations (PC’s) substantially consist of fees outstanding
under management agreements. Payment of the outstanding fees is dependent on collection by the PC’s of fees from third party medical
reimbursement organizations, principally insurance companies and health management organizations.
Payment
of the management fee receivables from the PC’s may be impaired by the inability of the PC’s to collect in a timely manner
their medical fees from the third party payors, particularly insurance carriers covering automobile no-fault and workers compensation
claims due to longer payment cycles and rigorous informational requirements and certain other disallowed claims. Approximately 67% and
66% of the PCs’ net revenues for the three months ended December 31, 2021 and 2020, respectively, were derived from no-fault and
personal injury protection claims. Approximately 67% and 66% of the PCs’ net revenue for the six months ended December 31, 2021
and 2020, respectively, were derived from no-fault and personal injury protection claims. The Company considers the aging of its accounts
receivable in determining the amount of allowance for doubtful accounts. The Company generally takes all legally available steps to collect
its receivables. Credit losses associated with the receivables are provided for in the condensed consolidated financial statements and
have historically been within management’s expectations.
FONAR
CORPORATION AND SUBSIDIARIES
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2021 and 2020
(Amounts
and shares in thousands, except per share amounts)
(UNAUDITED)
NOTE
3 – ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (CONTINUED)
Management and
Other Fees Receivable (Continued)
Net
revenues from management and other fees charged to the related PCs accounted for approximately 11.4% and 12.7% of the consolidated net
revenues for the three months ended December 31, 2021 and 2020, respectively. Net revenues from management and other fees charged to
the related PCs accounted for approximately 11.6% and 12.8% of the consolidated net revenues for the six months ended December 31, 2021
and 2020, respectively.
Tallahassee
Magnetic Resonance Imaging, PA, Stand Up MRI of Boca Raton, PA and Stand Up MRI & Diagnostic Center, PA (all related medical practices)
entered into a guaranty agreement, pursuant to which they cross guaranteed all management fees which are payable to the Company, which
have arisen under each individual management agreement. Additional Company managed entities also operate under a guaranty agreement,
pursuant to which management fees are payable to the Company.
The
Company’s patient fee revenue, net of contractual allowances and discounts for the three and six months ended December 31, 2021
and 2020 are summarized in the following table.
Schedule of patient
fee revenue
|
|
|
|
|
|
|
|
|
|
|
For
the Three Months Ended December 31,
|
|
|
2021
|
|
2020
|
Commercial
Insurance/ Managed Care
|
|
$
|
1,068
|
|
|
$
|
966
|
|
Medicare/Medicaid
|
|
|
273
|
|
|
|
206
|
|
Workers’
Compensation/Personal Injury
|
|
|
4,344
|
|
|
|
3,543
|
|
Other
|
|
|
1,758
|
|
|
|
523
|
|
Patient
Fee Revenue, net of contractual allowances and discounts
|
|
$
|
7,443
|
|
|
$
|
5,238
|
|
Management and
Other Fees Receivable (Continued)
|
|
For
the Six Months Ended December 31,
|
|
|
2021
|
|
2020
|
Commercial
Insurance/ Managed Care
|
|
$
|
2,154
|
|
|
$
|
1,912
|
|
Medicare/Medicaid
|
|
|
522
|
|
|
|
404
|
|
Workers’
Compensation/Personal Injury
|
|
|
8,468
|
|
|
|
6,930
|
|
Other
|
|
|
3,150
|
|
|
|
1,084
|
|
Patient
Fee Revenue, net of contractual allowances and discounts
|
|
$
|
14,294
|
|
|
$
|
10,330
|
|
FONAR
CORPORATION AND SUBSIDIARIES
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2021 and 2020
(Amounts
and shares in thousands, except per share amounts)
(UNAUDITED)
NOTE
4 – OPERATING & FINANCING LEASES
During
February 2016, FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to apply a dual approach, classifying leases
as either finance or operating leases based upon the principle of whether or not the lease is effectively a financed purchase by the
lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line
basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with
a term of greater than 12 months regardless of their classification. Lease with a term of 12 months or less will be accounted for similar
to existing guidance for operating leases. The standard was effective for us beginning July 1, 2019. We have elected the optional transition
method to apply the standard as of the effective date and therefore, we will not apply the standard to the comparative periods presented
in the consolidated financial statements. We have also elected the transition package of the practical expedients permitted within the
standard which eliminates the requirements to reassess prior conclusions about lease identification, lease classification and indirect
costs. The adoption of this guidance had a material impact on the Company’s balance sheet by virtue of including the present value
of its future operating lease payments as a liability of $33.3 million and related right-to-use lease assets as of July 1, 2019. At the
time of adoption of this guidance we had no significant financing leases.
The
Company accounts for its various operating leases in accordance with Accounting Standards Codification (‘ASC’) 842 –
Lease, as updated by ASU 2016-02. At the inception of a lease, the Company recognizes right-of-use lease assets and related lease liabilities
measured at present value of future lease payments on its balance sheet. Lease expense is recognized on a straight-line basis over the
term of the lease. Our most common initial term varies in length from 2 to 10 years. Including renewal options negotiated with the landlord,
we have a total span of 2 to 16 years at the facilities we lease. The Company reviewed its contracts with vendors and customers, determining
that its right-to-use lease assets consisted of only office space operating leases. In determining the right-to-use lease assets and
liabilities, the Company did recognize lease extension options which the Company feels would be reasonably exercised. Our incremental
borrowing rate (“IBR”) used to discount the stream of operating lease payments is closely related to the interest rates available
to the Company.
A
reconciliation of operating and financing lease payments undiscounted cash flows to lease liabilities recognized as of December 31, 2021
is as follows:
|
Reconcilliation
of operating and financing lease payments
|
|
|
|
|
|
|
|
|
|
Twelve
Months Ending December 31,
|
|
Operating
Lease Payments
|
|
Financing
Lease Payments
|
|
2022
|
|
|
$
|
5,282
|
|
|
$
|
244
|
|
|
2023
|
|
|
|
5,439
|
|
|
|
244
|
|
|
2024
|
|
|
|
5,247
|
|
|
|
244
|
|
|
2025
|
|
|
|
4,954
|
|
|
|
244
|
|
|
2026
|
|
|
|
4,410
|
|
|
|
244
|
|
|
Thereafter
|
|
|
|
22,755
|
|
|
|
42
|
|
|
Present
value discount
|
|
|
|
(10,814
|
)
|
|
|
(112
|
)
|
|
Total
lease liability
|
|
|
$
|
37,273
|
|
|
$
|
1,150
|
|
FONAR
CORPORATION AND SUBSIDIARIES
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2021 and 2020
(Amounts
and shares in thousands, except per share amounts)
(UNAUDITED)
NOTE 5 - INVENTORIES
Inventories
included in the accompanying condensed consolidated balance sheets consist of the following:
Inventories
|
|
|
|
|
|
|
|
|
|
|
December
31, 2021
|
|
June
30, 2021
|
Purchased
parts, components and supplies
|
|
$
|
1,859
|
|
|
$
|
1,393
|
|
Work-in-process
|
|
|
240
|
|
|
|
270
|
|
Total
Inventories
|
|
$
|
2,099
|
|
|
$
|
1,663
|
|
NOTE 6 –
CONTRACT ASSETS AND LIABILITIES
Information
relating to uncompleted contracts about contract assets and (liabilities) is as follows:
Costs
and Estimated Earnings on Uncompleted Contracts
|
|
|
|
|
|
|
|
|
|
|
December
31, 2021
|
|
June
30, 2021
|
Costs
incurred on uncompleted contracts
|
|
$
|
339
|
|
|
$
|
295
|
|
Estimated
earnings
|
|
|
524
|
|
|
|
568
|
|
Costs
and estimated earnings on uncompleted contracts
|
|
|
863
|
|
|
|
863
|
|
Less:
Billings to date
|
|
|
878
|
|
|
|
878
|
|
Total
costs and estimated earnings on uncompleted contracts
|
|
$
|
(15
|
)
|
|
$
|
(15
|
)
|
NOTE
7 – OTHER INTANGIBLE ASSETS
Other
intangible assets, net of accumulated amortization, in the accompanying condensed consolidated balance sheets consist of the following:
Other
Intagible Assets - Net
|
|
|
|
|
|
|
|
|
|
|
December
31, 2021
|
|
June
30, 2021
|
Capitalized
software development costs
|
|
$
|
7,005
|
|
|
$
|
7,005
|
|
Patents
and copyrights
|
|
|
5,283
|
|
|
|
5,245
|
|
Non-compete
|
|
|
4,150
|
|
|
|
4,150
|
|
Customer
relationships
|
|
|
3,900
|
|
|
|
3,900
|
|
Gross
Other intangible assets
|
|
|
20,338
|
|
|
|
20,300
|
|
Less:
Accumulated amortization
|
|
|
16,483
|
|
|
|
16,262
|
|
Other
Intangible Assets
|
|
$
|
3,855
|
|
|
$
|
4,038
|
|
FONAR
CORPORATION AND SUBSIDIARIES
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2021 and 2020
(Amounts
and shares in thousands, except per share amounts)
(UNAUDITED)
NOTE
7 – OTHER INTANGIBLE ASSETS (CONTINUED)
Amortization
of patents and copyrights for the three months ended December 31, 2021 and 2020 amounted to $49 and $44, respectively.
Amortization
of non-compete for the three months ended December 31, 2021 and 2020 amounted to $12 and $0, respectively.
Amortization
of customer relationships for the three months ended December 31, 2021 and 2020 amounted to $50 and $47, respectively.
Amortization
of patents and copyrights for the six months ended December 31, 2021 and 2020 amounted to $96 and $89, respectively.
Amortization
of non-compete for the six months ended December 31, 2021 and 2020 amounted to $25 and $0, respectively.
Amortization
of customer relationships for the six months ended December 31, 2021 and 2020 amounted to $100 and $95, respectively.
NOTE
8 – OTHER CURRENT LIABILITIES
Other
current liabilities in the accompanying condensed consolidated balance sheets consist of the following:
Other
Current Liabilities
|
|
|
|
|
|
|
|
|
|
|
December
31, 2021
|
|
June
30, 2021
|
Accrued
salaries, commissions and payroll taxes
|
|
$
|
2,141
|
|
|
$
|
5,407
|
|
Litigation
accruals
|
|
|
—
|
|
|
|
900
|
|
Sales
tax payable
|
|
|
543
|
|
|
|
645
|
|
State
income taxes payable
|
|
|
188
|
|
|
|
774
|
|
Legal
and other professional fees
|
|
|
11
|
|
|
|
38
|
|
Accounting
fees
|
|
|
116
|
|
|
|
127
|
|
Self-funded
health insurance reserve
|
|
|
—
|
|
|
|
62
|
|
Accrued
interest and penalty
|
|
|
105
|
|
|
|
493
|
|
Other
general & administrative expenses
|
|
|
1,513
|
|
|
|
716
|
|
Other
Current Liabilities
|
|
$
|
4,617
|
|
|
$
|
9,162
|
|
NOTE 9 - SEGMENT
AND RELATED INFORMATION
The
Company operates in two industry segments - manufacturing and the servicing of medical equipment and management of diagnostic imaging
centers. The accounting policies of the segments are the same as those described in the summary of significant accounting policies as
disclosed in the Company’s 10-K as of June 30, 2021. All inter-segment sales are market-based. The Company evaluates performance
based on income or loss from operations.
FONAR
CORPORATION AND SUBSIDIARIES
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2021 and 2020
(Amounts
and shares in thousands, except per share amounts)
(UNAUDITED)
NOTE 9 - SEGMENT
AND RELATED INFORMATION (CONTINUED)
Summarized
financial information concerning the Company’s reportable segments is shown in the following table:
Summarized
Segment Financial Information
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical
Equipment
|
|
Management
of Diagnostic
Imaging
Centers
|
|
Totals
|
For
the three months ended Dec, 31, 2021
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
revenues from external customers
|
|
$
|
2,133
|
|
|
$
|
22,346
|
|
|
$
|
24,479
|
|
Inter-segment
net revenues
|
|
$
|
239
|
|
|
$
|
—
|
|
|
$
|
239
|
|
(Loss)
Income from operations
|
|
$
|
(27
|
)
|
|
$
|
6,510
|
|
|
$
|
6,483
|
|
Depreciation
and amortization
|
|
$
|
68
|
|
|
$
|
1,121
|
|
|
$
|
1,189
|
|
Capital
expenditures
|
|
$
|
66
|
|
|
$
|
869
|
|
|
$
|
935
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For
the three months ended Dec. 31, 2020
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
revenues from external customers
|
|
$
|
1,893
|
|
|
$
|
19,271
|
|
|
$
|
21,164
|
|
Inter-segment
net revenues
|
|
$
|
219
|
|
|
$
|
—
|
|
|
$
|
219
|
|
(Loss)
Income from operations
|
|
$
|
(8
|
)
|
|
$
|
4,990
|
|
|
$
|
4,982
|
|
Depreciation
and amortization
|
|
$
|
65
|
|
|
$
|
977
|
|
|
$
|
1,042
|
|
Capital
expenditures
|
|
$
|
70
|
|
|
$
|
1,728
|
|
|
$
|
1,798
|
|
|
|
Medical
Equipment
|
|
Management
of Diagnostic
Imaging
Centers
|
|
Totals
|
For
the six months ended Dec, 31, 2021
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
revenues from external customers
|
|
$
|
4,245
|
|
|
$
|
43,964
|
|
|
$
|
48,209
|
|
Inter-segment
net revenues
|
|
$
|
475
|
|
|
$
|
—
|
|
|
$
|
475
|
|
(Loss)
Income from operations
|
|
$
|
(517
|
)
|
|
$
|
12,742
|
|
|
$
|
12,225
|
|
Depreciation
and amortization
|
|
$
|
135
|
|
|
$
|
2,223
|
|
|
$
|
2,358
|
|
Capital
expenditures
|
|
$
|
187
|
|
|
$
|
1,957
|
|
|
$
|
2,144
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For
the six months ended Dec. 31, 2020
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
revenues from external customers
|
|
$
|
3,874
|
|
|
$
|
38,270
|
|
|
$
|
42,144
|
|
Inter-segment
net revenues
|
|
$
|
438
|
|
|
$
|
—
|
|
|
$
|
438
|
|
(Loss)
Income from operations
|
|
$
|
(569
|
)
|
|
$
|
9,701
|
|
|
$
|
9,132
|
|
Depreciation
and amortization
|
|
$
|
132
|
|
|
$
|
1,878
|
|
|
$
|
2,010
|
|
Capital
expenditures
|
|
$
|
90
|
|
|
$
|
2,143
|
|
|
$
|
2,233
|
|
NOTE 10 –
SUPPLEMENTAL CASH FLOW INFORMATION
During
the six months ended December 31, 2021 and December 31, 2020, the Company paid $265 and $35 for interest, respectively.
During
the six months ended December 31, 2021 and December 31, 2020, the Company paid $572 and $145 for income taxes, respectively.
FONAR
CORPORATION AND SUBSIDIARIES
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2021 and 2020
(Amounts
and shares in thousands, except per share amounts)
(UNAUDITED)
NOTE 11 –
COMMITMENTS AND CONTINGENCIES
Litigation
The
Company is subject to legal proceedings and claims arising from the ordinary course of its business, including personal injury, customer
contract and employment claims. In the opinion of management, the aggregate liability, if any, with respect to such actions, will not
have a material adverse effect on the consolidated financial position or results of operations of the Company.
There
were no material changes in litigation from that reported in our Form 10-K for the fiscal year ended June 30, 2021.
Other Matters
In September 2019,
the Company was notified by one of its landlords that it was required to vacate the premises within 180 days under the demolition clause
in the lease. The Company believed the lease renewal which was not negotiated in good faith since the renewal was negotiated in February
2018. The Company has recently relocated to a new space but the original lease provided for penalty payments in the event that the Company
had not vacated the lease space. The Company had been making normal rent payments throughout the course of the arbitration proceedings.
The case was settled for $900 of leasehold holdover charges which was paid in August 2021.
In
September 2020, the Company entered into a settlement agreement with an unrelated third party for a claim made during March 2018 which
was scheduled for arbitration. The settlement was for $1.2 million of which $900 was paid by the Company’s insurance in September
2020. The Company paid the remaining balance of $315 in September 2020.
The
Company has satisfied most of its delinquencies in filing sales tax returns for certain states, for which the Company has transacted
business. The Company has recorded tax obligations of approximately $543 plus interest and penalties of approximately $60 until the remaining
states have been resolved.
The
Company maintains a self-funded health insurance program with a stop-loss umbrella policy with a third party insurer to limit the maximum
potential liability for individual claims to $150 per person and for a maximum potential claim liability based on member enrollment.
With respect to this program, the Company considers historical and projected medical utilization data when estimating its health insurance
program liability and related expense. As of December 31, 2021 and June 30, 2021, the Company had approximately $0 and $62, respectively,
in reserve for its self-funded health insurance programs. The reserves are included in “Other current liabilities” in the
condensed consolidated balance sheets.
The
Company regularly analyzes its reserves for incurred but not reported claims, and for reported but not paid claims related to its reinsurance
and self-funded insurance programs. The Company believes its reserves are adequate. However, significant judgment is involved in assessing
these reserves such as assessing historical paid claims, average lags between the claims’ incurred date, reported dates and paid
dates, and the frequency and severity of claims. There may be differences between actual settlement amounts and recorded reserves and
any resulting adjustments are included in expense once a probable amount is known. There were no significant adjustments recorded in
the periods covered by this report.
FONAR
CORPORATION AND SUBSIDIARIES
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2021 and 2020
(Amounts
and shares in thousands, except per share amounts)
(UNAUDITED)
NOTE 12 - INCOME
TAXES
In
accordance with ASC 740-270, Income Taxes – Interim Reporting, the Company is required at the end of each interim period to determine
the best estimate of its annual effective tax rate and apply that rate to year-to-date ordinary income or loss. The resulting tax expense
(or benefit) is adjusted for the tax effect of specific events, if any, required to be discretely recognized in the interim period as
they occur. For the six months ended December 31, 2021 and 2020, the Company recorded income tax expense of $2,846 in 2021 as compared
to $1,962 in 2020. The 2021 provision is comprised of a current income tax component of $409 and a deferred income tax component of $2,437.
Obligations for any liability associated with the current income tax provision, has been reduced, primarily resulting from the benefits
and utilization of net operating loss carryforwards.
ASC
topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax
positions taken or expected to be taken in a corporate tax return. For those benefits to be recognized, a tax position must be more-likely-than-not
to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return
and the benefit recognized and measured pursuant to the interpretation are referred to as unrecognized benefits. A liability is recognized
(or amount of net operating loss carryforward or amount of tax refundable is reduced) for an unrecognized tax benefit because it represents
an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying
the provisions of ASC topic 740. The Company believes there are no uncertain tax positions in prior years tax filings and therefore it
has not recorded a liability for unrecognized tax benefits.
In
accordance with ASC topic 740, interest costs related to unrecognized tax benefits are required to be calculated (if applicable) and
would be classified as “Interest expense, net”. Penalties if incurred would be recognized as a component of “Selling,
general and administrative” expenses.
The
Company files corporate income tax returns in the United States (federal) and in various state and local jurisdictions. In most instances,
the Company is no longer subject to federal, state and local income tax examinations by tax authorities for years prior to 2017.
The
Company recorded a deferred tax asset of $13,522 and a deferred tax liability of $ as of December 31, 2021, primarily relating to
net operating loss carryforwards of approximately $25,066 available to offset future taxable income through 2032. The net operating losses
begin to expire in 2023 for federal tax and state income tax purposes.
On
March 27, 2020 Congress enacted the CARES Act (Coronavirus Aid, Relief and Economic Security Act). The Act provides numerous tax provisions
and other stimulus measures, including temporary changes regarding prior and future operation losses, temporary changes to prior and
future limitations on interest deductions, temporary suspension of certain payment requirements for the employer portion of Social Security
taxes, technical corrections to prior tax legislation for tax depreciation of certain qualified improvement property and enhanced recoverability
of AMT tax credits.
At
the present time, the only impact of the CARES Act to the Company is allowing a full reimbursement of $1,342 of tax credits relating
to the alternative minimum tax credits. The Company received the first half payment in June 2020. The balance of alternative minimum
tax credits of $671 was received in July 2020. Previously, these credits were to be refunded over a 3 year period.
Future
ownership changes as determined under Section 382 of the Internal Revenue code could further limit the utilization of net operating loss
carryforwards. As of December 31, 2021, no such changes in ownership have occurred.
FONAR
CORPORATION AND SUBSIDIARIES
CONDENSED
CONSOLIDATED BALANCE SHEETS
(Amounts
and shares in thousands, except per share amounts)
(UNAUDITED)
NOTE 12 - INCOME
TAXES (CONTINUED)
The
ultimate realization of deferred tax assets is dependent on the generation of future taxable income during the periods in which those
temporary differences become deductible or when such net operating losses can be utilized. The Company considers projected future taxable
income, the regulatory environment of the industry and tax planning strategies in making this assessment. At present, the Company believes
that it is more likely than not that the benefits from certain deferred tax asset carryforwards, will not all be fully realized. In recognition
of this inherent risk, a valuation allowance was established for the partial value of the deferred tax asset, which principally related
to research and development tax credits. A valuation allowance will be maintained until sufficient positive evidence exists to support
the reversal of the remainder of the valuation.
NOTE 13 –
ACQUISITION
On
March 29, 2021, the Company completed the acquisition of certain assets of Rockland Management Group, located in West Yonkers. The Company
used an incremental borrowing rate of 4% to value the right to use asset in connection with the assumed operating lease obligation. We
made a preliminary fair value determination of the acquired assets and assumed liabilities as follows:
Fair
value assets and assumed liabilities
|
|
|
|
|
Property
and equipment
|
|
$
|
650
|
|
Right
to use assets
|
|
|
434
|
|
Intangible
assets
|
|
|
150
|
|
Security
Deposit
|
|
|
39
|
|
Right
to use liability
|
|
|
(434
|
)
|
Goodwill
|
|
|
284
|
|
Total
purchase consideration
|
|
$
|
1,123
|
|
In
accordance with ASC 805-10-25-1, Business Combinations – Overall Recognition, the Company recorded the transaction as a
business combination. ASC 805-10-25-1 provides the requirements of recording the transaction by applying the acquisition method. The
acquisition method requires the Company to determine if the assets and liabilities acquired are a business or not. Under ASC 805-10-25-1,
it must be determined if there is a specific acquisition party, acquisition date, identifiable assets acquired and liabilities assumed
and you must be able to recognized and measure goodwill or a gain from the purchase. Based upon this guidance, the acquisition had been
recorded as a business combination.
The net assets
acquired and consideration is as follow:
Net
assets acquired
|
|
|
|
|
Leasehold
Improvements
|
|
$
|
550
|
|
Diagnostic
Equipment
|
|
|
100
|
|
Customer
Lists
|
|
|
100
|
|
Covenant
Not to Compete
|
|
|
50
|
|
Security
Deposit
|
|
|
39
|
|
Closing
costs – expensed
|
|
|
3
|
|
Goodwill
|
|
|
284
|
|
Cash
Consideration Paid
|
|
$
|
1,126
|
|
The
results of operations of Rockland Management Group were diminutive and did not affect the pro forma results of operations.
NOTE
14 – SUBSEQUENT EVENTS
The
Company has evaluated events that occurred subsequent to December 31, 2021 and through the date the condensed consolidated financial
statements were issued.
FONAR
CORPORATION AND SUBSIDIARIES